

# A Comprehensive Review on Formulation Aspects of Amla (*Emblica officinalis* Gaertn.): Phytochemistry, Dosage Forms, and Therapeutic Applications

**Rathod Karan Krushna, Pokharkar Pratik Suresh, Ass Prof Mr. Gadage Ashish Rambhau  
Satpute Prajwal Ravindra, Dr. Lokhande R. P., Ass Prof. Mr. Gadge S.C**

karankrathod7671@gmail.com  
Samarth Institute of Pharmacy, Belhe

**Abstract:** *Amla (Emblica officinalis Gaertn.), also known as Indian Gooseberry, is one of the most revered medicinal plants in Ayurvedic medicine. It is an exceptionally rich source of Vitamin C, tannins, flavonoids, polyphenols, and other bioactive compounds with diverse pharmacological activities including antioxidant, anti-inflammatory, immunomodulatory, hepatoprotective, cardioprotective, and antimicrobial properties. Despite its immense therapeutic potential, the formulation of amla presents significant challenges due to the instability of its active constituents, particularly ascorbic acid, under varying pH, temperature, and oxidative conditions. This review comprehensively discusses the phytochemical profile of Emblica officinalis, various extraction and standardization methods, and innovative formulation strategies including tablets, capsules, syrups, creams, gels, nanoparticles, solid lipid nanoparticles (SLNs), niosomes, liposomes, and mucoadhesive formulations. The review also highlights evaluation parameters for each dosage form and the challenges encountered during formulation development. This article aims to serve as a structured reference for researchers, students, and formulators working in the domain of herbal pharmaceuticals.*

**Keywords:** Emblica officinalis, Amla, Indian Gooseberry, Herbal Formulation, Nanoparticles, Phytochemistry, Dosage Forms, Antioxidant, Vitamin C, Tannins

## I. INTRODUCTION

*Emblica officinalis* Gaertn. (Family: Phyllanthaceae), commonly known as Amla or Indian Gooseberry, is one of the oldest and most important medicinal plants described in Ayurvedic texts such as Charaka Samhita and Sushruta Samhita. The plant is a medium-sized deciduous tree found abundantly across India, Sri Lanka, Malaysia, and China. The fruit of *Emblica officinalis* is the primary part used medicinally and has been an integral component of classical formulations such as Triphala, Chyawanprash, and Amalaki Rasayana.

The fruit is nutritionally significant due to its extraordinarily high content of Vitamin C (ascorbic acid), estimated to be 20 times higher than that of orange. Beyond vitamin C, the fruit is rich in ellagic acid, gallic acid, emblicanin A and B, punigluconin, pedunculagin, chebulinic acid, and various flavonoids. These bioactive constituents collectively contribute to the wide-ranging pharmacological activities attributed to the plant.

From a pharmaceutical perspective, Amla presents both promise and challenges. While its therapeutic potential is immense, formulating stable and bioavailable dosage forms from Amla extract requires careful attention to the physicochemical properties of its active constituents. This review consolidates available literature on formulation-based research on *Emblica officinalis*, covering conventional and novel drug delivery systems, with a focus on evaluation parameters and stability considerations.



## II. PLANT PROFILE

### 2.1 Plant Image



### 2.2 Taxonomical Classification

Category	Description
Kingdom	Plantae
Division	Magnoliophyta
Class	Magnoliopsida
Order	Malpighiales
Family	Phyllanthaceae
Genus	Emblica
Species	officinalis
Binomial Name	Emblica officinalis Gaertn.
Synonyms	Phyllanthus emblica Linn.
Common Names	Amla, Amlika, Indian Gooseberry, Aavla (Marathi)

### 2.3 Morphology

*Emblica officinalis* is a small to medium-sized deciduous tree growing up to 8–18 meters in height. The bark is grayish-brown, thin, and exfoliating in small flakes. Leaves are simple, sessile, linear-oblong, arranged in two ranks giving a pinnate appearance. Flowers are small, yellowish-green, and unisexual. The fruit is fleshy, globose, 1.5–2.5 cm in diameter, pale greenish-yellow with six vertical furrows, and contains six seeds. The fruit is the primary medicinal part and is harvested between October and February.

### 2.4 Geographical Distribution

The plant is native to tropical and subtropical regions of Asia. In India, it is found throughout the subcontinent from the Himalayas to Sri Lanka, and is commercially cultivated in Uttar Pradesh, Madhya Pradesh, Tamil Nadu, Rajasthan, and Maharashtra. It grows well in tropical moist deciduous and dry deciduous forests at altitudes up to 1,500 meters.



### III. PHYTOCHEMICAL CONSTITUENTS

The fruit of *Emblica officinalis* is a rich reservoir of bioactive phytochemicals. These constituents vary depending on the geographical origin, season of collection, and extraction method used.

Phytochemical Class	Constituents	Activity
Vitamin C (Ascorbic Acid)	Free ascorbic acid (445–3640 mg/100g)	Antioxidant, Immunomodulatory
Tannins	Emblicanin A & B, Punigluconin, Pedunculagin, Chebulinic acid	Antioxidant, Astringent, Antimicrobial
Polyphenols / Ellagitannins	Ellagic acid, Gallic acid, Corilagin	Hepatoprotective, Anticancer
Flavonoids	Quercetin, Kaempferol, Rutin	Anti-inflammatory, Antioxidant
Alkaloids	Phyllantine, Phyllembin	CNS activity
Terpenoids	Lupeol, Beta-sitosterol	Anti-inflammatory
Organic Acids	Oxalic acid, Citric acid, Malic acid	pH modulation
Polysaccharides	Pectin, Mucilage	Binding, Demulcent
Fixed Oils	Linolenic acid, Palmitic acid	Emollient

Note: The stability of ascorbic acid in Amla preparations is a major formulation concern. Emblicanins A and B are unique tannin-vitamin C complexes that confer greater stability to ascorbic acid compared to synthetic forms. This property is exploited in formulation strategies to maintain activity during storage.

### IV. EXTRACTION AND STANDARDIZATION

#### 4.1 Extraction Methods

The selection of an appropriate extraction method is critical for obtaining a phytochemically rich and stable extract of *Emblica officinalis*.

Method	Solvent Used	Yield / Advantage	Limitation
Maceration	Water, 70% Ethanol	Simple, low cost	Long time, variable yield
Soxhlet Extraction	Methanol, Ethanol	High yield, reproducible	Thermal degradation of Vit C
Aqueous Decoction	Water	Traditional, safe	Microbial contamination risk
Hydroalcoholic Extraction	50–70% Ethanol	Balanced polarity	Moderate yield
Supercritical CO <sub>2</sub>	CO <sub>2</sub> (SCFE)	No solvent residue, stable	Expensive equipment



Method	Solvent Used	Yield / Advantage	Limitation
Ultrasonication-Assisted	Water/Ethanol	Fast, high efficiency	Heat generated
Spray Drying	Aqueous extract	Good for powder form	Cost, possible degradation

#### 4.2 Standardization Parameters

Standardization of Amla extract must conform to pharmacopoeial guidelines. Key parameters include:

Total phenolic content (TPC) — expressed as mg Gallic Acid Equivalent (GAE)/g

Ascorbic acid content — by HPLC or titrimetric method (2,6-DCPIP titration)

Total tannin content — by Folin-Ciocalteu method

Heavy metal testing — Pb, As, Cd, Hg limits as per WHO

Loss on drying (LOD), Ash value, Extractive value

Microbial limit test — TAMC and TYMC

HPLC fingerprinting — marker: Gallic acid, Ellagic acid

### V. FORMULATION-BASED RESEARCH ON EMBLICA OFFICINALIS

#### 5.1 Conventional Dosage Forms

##### 5.1.1 Tablets and Capsules

Amla extract tablets are among the most commonly marketed formulations. Challenges include poor compressibility of dry extract, hygroscopicity, and chemical instability of ascorbic acid. Microcrystalline cellulose (MCC), lactose, and HPMC are used as diluents. Enteric coating using Eudragit L100 or HPMC phthalate is applied to prevent degradation in acidic gastric pH.

Hard gelatin capsules filled with Amla powder or spray-dried extract are stable for 18–24 months when stored below 25°C with desiccant. Typical dose: 500 mg–1 g per capsule. Extended-release capsules using Kollidon SR and HPMC K100M have been reported with 8–12 hour release profiles.

##### 5.1.2 Syrups and Oral Liquids

Amla syrups are traditionally prepared using sugar as the base. Modern formulations replace sugar with stevia, sorbitol, or xylitol for diabetic-friendly preparations. The major challenge is microbial stability and color change due to oxidation of Vitamin C. Sodium metabisulfite (0.1%) as antioxidant and sodium benzoate (0.1%) as preservative are commonly added. pH is maintained between 3.5–5.5.

Typical syrup formulation: Amla extract 5–10% w/v, Sucrose/Stevia, Citric acid, Sodium benzoate, Sodium metabisulfite, Purified water q.s. Evaluation: pH, viscosity, specific gravity, microbial count, Vitamin C content, accelerated stability.

##### 5.1.3 Powders (Churna)

Amla Churna is the most traditional Ayurvedic dosage form. The dried fruit is powdered (sieve No. 85, 180 µm) and standardized for total phenolics and ascorbic acid. Problems include hygroscopicity and possible Maillard reaction with added excipients. Encapsulation in moisture-barrier blisters or airtight containers extends shelf life.



## **5.2 Topical Formulations**

### **5.2.1 Creams and Lotions**

Amla extract-based creams are formulated for skin lightening, anti-aging, and photoprotective applications. The extract (1–5% w/w) is incorporated into oil-in-water (O/W) emulsions. Emulsifying agents include Tween 80, cetostearyl alcohol, and glyceryl monostearate. Preservatives: methylparaben/propylparaben combination.

Gallic acid and ellagic acid in Amla inhibit tyrosinase enzyme, reducing melanin synthesis. Studies report SPF values of 8–12 for Amla-containing creams. Stability challenges: color change, phase separation, and microbial growth.

### **5.2.2 Gels**

Carbopol 934 (0.5–1%) and HPMC (1–2%) are commonly used gelling agents for Amla extract gels. Applications include anti-acne gels (due to antimicrobial activity), hair gels (for scalp nourishment), and wound healing gels. Evaluated for pH (6.0–7.5), viscosity, spreadability, drug content, and ex vivo permeation.

### **5.2.3 Hair Oils and Shampoos**

Amla oil is a traditional hair care product prepared by boiling Amla fruit or extract in sesame or coconut oil. Cosmetic shampoo formulations incorporating 2–5% Amla extract exhibit improved foaming, scalp conditioning, and antidandruff activity due to antimicrobial tannins. Standardization is done by assay of gallic acid content.

## **5.3 Novel Drug Delivery Systems (NDDS)**

### **5.3.1 Nanoparticles**

Polymeric nanoparticles of Amla extract have been prepared using PLGA (poly lactic-co-glycolic acid) and chitosan by nanoprecipitation and ionic gelation methods respectively. Particle size range: 150–400 nm. Zeta potential: -20 to -35 mV (good stability). Encapsulation efficiency: 65–85%. Applications: enhanced oral bioavailability, sustained release.

### **5.3.2 Solid Lipid Nanoparticles (SLN)**

SLNs of Amla extract are prepared using lipid matrices such as glyceryl monostearate, Compritol 888 ATO, and Precirol ATO 5 with Tween 80 as surfactant. The SLN system protects the labile vitamin C from oxidation and improves topical delivery. Particle size: 100–300 nm. Studies show 2.5-fold increase in skin permeation compared to conventional cream.

### **5.3.3 Liposomes**

Phosphatidylcholine-based liposomes loaded with Amla gallic acid have been prepared by thin film hydration method. Entrapment efficiency: 55–75%. Liposomal encapsulation improves cellular uptake and provides sustained release. Applications in cosmeceuticals and oral delivery for antioxidant activity.

### **5.3.4 Niosomes**

Span 60 and cholesterol-based niosomes of Amla extract have been prepared by reverse phase evaporation. Vesicle size: 200–500 nm. Niosomes offer advantages of low cost, better stability than liposomes, and improved dermal delivery. Evaluated for vesicle size, zeta potential, entrapment efficiency, and in vitro release.

### **5.3.5 Microspheres**

Amla extract microspheres prepared by solvent evaporation method using ethyl cellulose and HPMC showed sustained release up to 12 hours. Particle size: 50–200  $\mu\text{m}$ . Evaluated for percentage yield, drug loading, swelling index, and in vitro dissolution. Applications: colon-targeted delivery for gastrointestinal disorders.



### 5.3.6 Nanoemulsions

Oil-in-water nanoemulsions of Amla essential oil have been prepared using high-energy emulsification (homogenization). Droplet size: 50–200 nm. Nanoemulsions improve solubility and bioavailability of lipophilic components of Amla and show better antimicrobial activity compared to bulk oil.

## VI. EVALUATION PARAMETERS

Dosage Form	Key Evaluation Parameters
Tablets/Capsules	Hardness, Friability, Disintegration time, Drug content, Dissolution profile (USP Apparatus II), Stability (ICH Q1A)
Syrups	pH, Viscosity, Specific gravity, Refractive index, Microbial limit, Vitamin C assay, Color stability
Creams/Gels	pH, Spreadability, Viscosity, Drug content, In vitro release, Skin irritation, SPF
Nanoparticles/SLN	Particle size (DLS), Zeta potential, PDI, Encapsulation efficiency, In vitro release, TEM/SEM morphology
Liposomes/Niosomes	Vesicle size, Entrapment efficiency, Zeta potential, Stability, In vitro permeation, DSC
Powders (Churna)	Particle size, LOD, Total ash, Acid-insoluble ash, Total phenolics, HPLC fingerprint

## VII. PHARMACOLOGICAL ACTIVITIES RELEVANT TO FORMULATION

Activity	Mechanism	Relevant Formulation
Antioxidant	Free radical scavenging (DPPH, ABTS), Vit C, Tannins	Capsules, Syrups, Creams
Anti-inflammatory	COX-2 inhibition, NF- $\kappa$ B pathway	Gels, Topical creams
Antimicrobial	Tannin-mediated membrane disruption, ZOI against <i>S. aureus</i> , <i>E. coli</i>	Syrups, Mouth gels, Shampoos
Hepatoprotective	Reduction of SGOT, SGPT; Antioxidant activity	Capsules, Tablets
Immunomodulatory	Enhancement of NK cell, macrophage activity	Oral formulations
Cardioprotective	Lipid peroxidation inhibition, ACE inhibition	Oral liquids, Tablets
Antidiabetic	Alpha-glucosidase inhibition, Insulin secretion	Oral capsules
Anticancer	Apoptosis induction, Angiogenesis inhibition	Nanoparticles, Liposomes



Activity	Mechanism	Relevant Formulation
Skin Lightening	Tyrosinase inhibition by gallic acid	Creams, Lotions, Serums

## VIII. FORMULATION CHALLENGES AND SOLUTIONS

### 8.1 Stability of Ascorbic Acid

Vitamin C is highly susceptible to oxidation, particularly at alkaline pH, elevated temperatures, and in the presence of metal ions (Fe<sup>2+</sup>, Cu<sup>2+</sup>). Strategies to address this include: use of antioxidants (sodium metabisulfite, BHA, BHT), chelating agents (EDTA), nitrogen purging during manufacturing, and encapsulation in protective matrices (SLN, liposomes, microspheres).

### 8.2 Hygroscopicity

Amla extract powder is highly hygroscopic due to tannins and polysaccharides. Solutions include spray drying with maltodextrin as carrier, use of moisture-barrier packaging (Al-Al blister), and storage with desiccant (silica gel) at low humidity (<30% RH).

### 8.3 Bitter Taste

The astringency of tannins causes palatability problems in oral liquids and chewable tablets. Taste masking approaches include: microencapsulation, use of sweeteners (stevia, aspartame), ion-exchange resins (Amberlite IRP69), and flavoring agents (mango, honey flavors).

### 8.4 Bioavailability

Despite high Vitamin C content, bioavailability can be limited due to first-pass metabolism and short half-life. Novel delivery systems such as nanoparticles, nanoemulsions, and mucoadhesive formulations have been explored to improve bioavailability.

## IX. MARKETED FORMULATIONS

Product Name	Manufacturer	Dosage Form	Indication
Dabur Amla Gold Hair Oil	Dabur India Ltd.	Oil	Hair nourishment
Himalaya Amalaki	Himalaya Drug Company	Tablet (500 mg)	Antioxidant, Immunomodulatory
Patanjali Amla Juice	Patanjali Ayurved	Oral Liquid	General health, Digestion
Chyawanprash	Multiple brands	Herbal Jam (Semi-solid)	Immunomodulatory, Adaptogenic
Triphala Churna	Multiple brands	Powder	Digestive, Laxative
Amla Candy	Multiple brands	Confection	Vitamin C supplementation
Zandu Amlapitta Mishran	Zandu Realty Ltd.	Syrup	Hyperacidity, Gastric disorders



### X. CONCLUSION

*Emblica officinalis* (Amla) stands as a potent and versatile medicinal plant with an unparalleled phytochemical profile. Its rich content of Vitamin C, tannins, polyphenols, and flavonoids has been harnessed in a wide range of formulations — from traditional Ayurvedic Churna and Syrups to advanced novel drug delivery systems including nanoparticles, liposomes, and SLNs. The formulation of Amla presents unique challenges, particularly around the stability of ascorbic acid and tannin hygroscopicity, which have been addressed through innovative encapsulation strategies and process optimization.

Future research should focus on clinical validation of nano-formulations of Amla, standardization protocols for NDDS, and development of combination formulations with complementary herbal extracts. The integration of quality by design (QbD) principles in Amla formulation development will help ensure consistent quality and therapeutic efficacy. Amla holds tremendous potential not only in pharmaceutical formulations but also in nutraceuticals and cosmeceuticals, making it a plant of immense scientific and commercial interest.

### REFERENCES

1. Krishnaveni M, Mirunalini S. Therapeutic potential of *Phyllanthus emblica* (amla): the ayurvedic wonder. *Journal of Basic and Clinical Physiology and Pharmacology*. 2010;21(1):93–105.
2. Dasaroju S, Gottumukkala KM. Current trends in the research of *Emblica officinalis* (Amla): a pharmacological perspective. *International Journal of Pharmaceutical Sciences Review and Research*. 2014;24(2):150–159.
3. Garg V, Kashyap M, Garg C. *Emblica officinalis* – A Review. *Journal of Pharmaceutical Research*. 2012;5(9):4819–4823.
4. Sharma N, Trikha P, Athar M, Raisuddin S. Inhibitory effect of *Emblica officinalis* on oxidative stress-induced cytotoxicity in human blood leukocytes. *Phytotherapy Research*. 2000;14(6):463–465.
5. Bhattacharya A, Chatterjee A, Ghoshal S, Bhattacharya SK. Antioxidant activity of active tannoid principles of *Emblica officinalis*. *Indian Journal of Experimental Biology*. 1999;37:676–680.
6. Yokozawa T, Kim HY, Kim HJ, Tanaka T, Sugino H, Okubo T, et al. Amla (*Emblica officinalis* Gaertn.) prevents dyslipidaemia and oxidative stress in the ageing process. *British Journal of Nutrition*. 2007;97(6):1187–1195.
7. Perianayagam JB, Sharma SK, Joseph A, Christina AJ. Evaluation of anti-pyretic and analgesic activity of *Emblica officinalis* Gaertn. *Journal of Ethnopharmacology*. 2004;95(1):83–85.
8. Singh I, Singh VP. Antifungal properties of aqueous and organic solvent extracts of seed and leaf of *Emblica officinalis* Gaertn. *Indian Phytopathology*. 2000;53:458–461.
9. Poltanov EA, Shikov AN, Dorman HJ, Pozharitskaya ON, Makarov VG, Tikhonov VP, et al. Chemical and antioxidant evaluation of Indian gooseberry (*Emblica officinalis* Gaertn., syn. *Phyllanthus emblica* L.) supplements. *Phytotherapy Research*. 2009;23(9):1309–1315.
10. Sairam K, Rao CV, Babu MD, Kumar KV, Agrawal VK, Goel RK. Antiulcerogenic effect of methanolic extract of *Emblica officinalis*: an experimental study. *Journal of Ethnopharmacology*. 2002;82(1):1–9.
11. Anila L, Vijayalakshmi NR. Beneficial effects of flavonoids from *Sesamum indicum*, *Emblica officinalis* and *Momordica charantia*. *Phytotherapy Research*. 2000;14(8):592–595.
12. Akhtar MS, Ramzan A, Ali A, Ahmad M. Effect of Amla fruit (*Emblica officinalis* Gaertn.) on blood glucose and lipid profile of normal subjects and type 2 diabetic patients. *International Journal of Food Sciences and Nutrition*. 2011;62(6):609–616.
13. Mir AI, Kumar B, Saraf SA. Amla (*Emblica officinalis*): a review for its phytochemistry, ethnobotanical uses and medicinal potentials. *International Journal of Research in Pharmaceutical and Biomedical Sciences*. 2012;3(4):
14. Kumar KS, Bhowmik D, Chiranjib B, Tiwari P. *Emblica officinalis*: a novel and natural source of C-glycosylated flavone with varied pharmacological activities. *Journal of Applied Pharmaceutical Science*. 2011;1(1):91–99.
15. Chaudhary AK, Kumar M, Singh M. Development and evaluation of Amla (*Emblica officinalis*) extract-based herbal formulations for topical application. *Asian Journal of Pharmaceutics*. 2014;8(3):152–158.

